Research Analysts Issue Forecasts for CATX Q1 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX) – Equities researchers at Wedbush boosted their Q1 2025 EPS estimates for shares of Perspective Therapeutics in a report issued on Wednesday, March 26th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.31) per share for the quarter, up from their prior estimate of ($0.37). Wedbush has a “Outperform” rating and a $11.00 price objective on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Wedbush also issued estimates for Perspective Therapeutics’ Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.53) EPS, FY2026 earnings at ($1.63) EPS and FY2027 earnings at ($1.73) EPS.

A number of other analysts have also recently commented on CATX. Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Royal Bank of Canada decreased their target price on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Thursday, March 27th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Perspective Therapeutics in a report on Monday. Brookline Capital Management upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. Finally, Scotiabank initiated coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 target price for the company. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, Perspective Therapeutics presently has an average rating of “Buy” and a consensus price target of $14.44.

Perspective Therapeutics Price Performance

Shares of CATX opened at $1.96 on Monday. The company’s fifty day moving average price is $2.88 and its 200-day moving average price is $6.10. Perspective Therapeutics has a 1-year low of $1.90 and a 1-year high of $19.05.

Hedge Funds Weigh In On Perspective Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Y Intercept Hong Kong Ltd purchased a new stake in shares of Perspective Therapeutics during the fourth quarter worth about $33,000. Intech Investment Management LLC acquired a new stake in Perspective Therapeutics in the 3rd quarter worth about $137,000. Aigen Investment Management LP purchased a new stake in Perspective Therapeutics during the 4th quarter worth approximately $34,000. National Bank of Canada FI raised its holdings in shares of Perspective Therapeutics by 549,900.0% during the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock valued at $35,000 after acquiring an additional 10,998 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Perspective Therapeutics during the third quarter valued at approximately $152,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Perspective Therapeutics

In other Perspective Therapeutics news, Director Robert F. Williamson III acquired 22,192 shares of the company’s stock in a transaction on Friday, March 28th. The shares were bought at an average cost of $2.27 per share, with a total value of $50,375.84. Following the completion of the acquisition, the director now owns 70,837 shares in the company, valued at approximately $160,799.99. This trade represents a 45.62 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Juan Graham acquired 33,333 shares of the business’s stock in a transaction dated Friday, March 28th. The stock was acquired at an average price of $2.25 per share, with a total value of $74,999.25. Following the completion of the transaction, the chief financial officer now directly owns 35,354 shares of the company’s stock, valued at approximately $79,546.50. This represents a 1,649.33 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 115,696 shares of company stock valued at $256,344. Corporate insiders own 3.52% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.